BCLI BrainStorm Cell Therapeutics Inc.: Price-to-Projected Revenue Ratio
Brainstorm Cell (BCLI) minimizes infrastructure risks by utilizing external cGMP facilities for the production of cellular products. The forward price-to-sales ratio confirms this strategy, with the metric serving as the target level. Business development depends on clinical success in treating ALS rather than market cycles. Strict sanitary control during the disposal of biomaterials ensures the environmental safety of the research.
Summary analytical data breakdowns for BrainStorm Cell Therapeutics Inc. (BCLI)
- market price and analyst price targets:
- company stock capitalization data:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital Brainstorm Cell|BCLI - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Brainstorm Cell|BCLI - Company Cumulative Debt|Debt to Book Capitalization Ratio BrainStorm Cell Therapeutics Inc.|BCLI - Company Long-Term Debt|Company Short-Term Debt BrainStorm Cell Therapeutics|Quick Ratio brainstorm-cell.com
- business earnings and investment ratios data:
BCLI - Company Net Income|Projected Future Earnings Brainstorm Cell|BCLI - Price to Earnings Ratio|Future Price to Earnings Brainstorm Cell Therapeutics, Inc.|BCLI - Price/Earnings to Growth Ratio|EV/EBITDA Multiple BrainStorm Cell Therapeutics Inc.|BCLI - Operating income before deduction of amortization|Earnings per share for the last twelve months BrainStorm Cell Therapeutics|BCLI - Earnings per share for the last 12 months|Quarterly EPS earnings growth brainstorm-cell.com|BCLI - Earnings per share growth rate in current year|Expected earnings per share growth for next year Brainstorm Cell
- sales and revenue data:
Initial company analysis:BCLI (BrainStorm Cell Therapeutics)
The specifics of Brainstorm Cell (BCLI) and its long-term anticipation of FDA approval make the forward price-to-sales ratio a key tool for assessing the business's resilience to cost inflation. This chart reflects market expectations for future sales, allowing investors to promptly identify capital vulnerabilities and the impact of R&D expenses on asset value without waiting for quarterly reports.
Who Brainstorm Cell competes with
Price-to-Projected Revenue Ratio Biogen BIIB|Neurocrine (NBIX) - Market Cap to Future Revenue Ratio|RGC - Price-to-Projected Revenue Ratio|Forward Price to Sales AXSM (Axsome Corp)|ACADIA Pharmaceuticals (ACAD) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple xenon-pharma.com|Forward Price-to-Revenue Multiple VKTX|SUPN: Forward Price to Sales|Forward P/S Multiple CPRX|Forward Price-to-Revenue Multiple Denali Corp DNLI|Forward P/S Multiple HRMY (Harmony Biosciences)|biohavenpharma.com (BHVN) - Market Cap to Future Revenue Ratio|AMLX - Price-to-Projected Revenue Ratio|TRVI: Price-to-Projected Revenue Ratio|Praxis Medicines (PRAX) - Price-to-Projected Revenue Ratio|AVXL (Anavex Life Sciences Corp) - Price-to-Projected Revenue Ratio|CBLL (CeriBell, Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio PRTA|Forward P/S Multiple ALEC|Forward Price-to-Revenue Multiple Annexon Biosciences ANNX|Price-to-Projected Revenue Ratio Omeros OMER|Neurogene Therapeutics - Price-to-Projected Revenue Ratio|AC Immune - Forward P/S Multiple|Market Cap to Expected Sales Ratio voyagertherapeutics.com VYGR|Neumora Therapeutics, Inc. (NMRA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue SCLX|TVGN (Tevogen Bio Holdings, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Alpha Cognition Corp ACOG|Forward Price-to-Revenue Multiple CGTX (Cognition Therapeutics)|Forward P/S Multiple inhibikase.com (IKT)|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|Forward Price to Sales ASRT|COYA - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vistagen Therapeutics|OVID: Forward P/S Multiple|ABOS (acumenpharm.com) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio CervoMed|ATHE: Forward Price to Sales|Forward P/S Multiple CLNN|Forward P/S Multiple pepgen.com (PEPG)|Forward P/S Multiple JUNS (Jupiter Neurosciences Inc)|Market Cap to Expected Sales Ratio relmada.com (RLMD)|ANVS - Price-to-Projected Revenue Ratio|GRCE (Grace Therapeutics, Inc.) - Market Cap to Projected Revenue|Firefly Neuroscience Inc (AIFF) - Price-to-Projected Revenue Ratio|KLTO - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple NRSN|RVPH (revivapharma.com) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio MetaVia Inc (MTVA)|NRXS - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Helius Medical Technologies HSDT|Forward Price to Sales PASG|NEUP - Price-to-Projected Revenue Ratio|minervaneurosciences.com (NERV) - Forward Price-to-Revenue Multiple|ATHA (Athira Pharma) - Forward Price-to-Revenue Multiple|Addex Therapeutics Ltd. - Forward Price to Sales|ALZN (Alzamend Neuro Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Cyclerion (CYCN)|Forward P/S Multiple PTIX|KTTA - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Cortigent CRGT|Avenue Therapeutics Inc. - Price-to-Projected Revenue Ratio|CARA - Price-to-Projected Revenue Ratio|CHRO: Price-to-Projected Revenue Ratio|ELYM: Forward P/S Multiple|ITCI (Intra-Cellular Therapies, Inc.) - Price-to-Projected Revenue Ratio|LBPH (Longboard Pharmaceuticals, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Marinus Pharmaceuticals Inc (MRNS)|Price-to-Projected Revenue Ratio NKGen (NKGN)|Price-to-Projected Revenue Ratio NRBO (NeuroBo Pharma)|Forward P/S Multiple SAGE (Sage Therapeutics, Inc.)|Market Cap to Expected Sales Ratio synaptogen.com (SNPX)|TRVN - Price-to-Projected Revenue Ratio|VIGL (Vigil Neuroscience) - Market Cap to Projected Revenue|WENA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Cerevel Corp (CERE)
